Staying the Course in Endovascular AAA Repair

The legal troubles and withdrawal of Guidant from the endovascular abdominal arotic aneurysm repair market may have cast a pall on public perception of the procedure, but competitors advancing new devices towards the market believe it just means a bigger piece of the pie for everyone.

The legal troubles and withdrawal of Guidant Corp. from the endovascular abdominal aortic aneurysm (AAA) repair market may have cast a pall on public perception of the procedure, but competitors advancing new devices towards the market believe it just means a bigger piece of the pie for everyone else. The exit of one of the top three AAA device players (the others are Medtronic Inc. , far and away the US market leader, and Cook Group Inc. , which dominates the market in Europe) was no shock to other endovascular AAA repair companies. They've always been aware of the risks of working in a market where the degree of difficulty of the technical challenges is far closer to an extreme marathon than to a cakewalk.

Aneurysms in the abdominal aorta, a very large (normally an inch in diameter) blood vessel that leads from the heart...

More from Archive

More from In Vivo

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Thinking Outside The BIOX: Bioxodes Takes Novel Approach To Intracerebral Hemorrhage

 
• By 

Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.